No Data
No Data
We're Hopeful That Acrivon Therapeutics (NASDAQ:ACRV) Will Use Its Cash Wisely
Acrivon Therapeutics Reports Promising Clinical Progress and Financial Results
Maxim Group Maintains Acrivon Therapeutics(ACRV.US) With Buy Rating, Maintains Target Price $24
Acrivon Therapeutics Is Maintained at Outperform by BMO Capital
BMO Capital Maintains Acrivon Therapeutics(ACRV.US) With Buy Rating, Cuts Target Price to $27
Oppenheimer Maintains Acrivon Therapeutics(ACRV.US) With Buy Rating, Maintains Target Price $18
No Data
JESSE JAMES8832 : i expeced so much better for this
JESSE JAMES8832 : maybe fill that gap to 6.62?
Trytosaveabit OP JESSE JAMES8832 : Yup! But look at PCSA! It gets just a PT increase and flyin! This gets great news and a PT increase and dud? Hehehe
Trytosaveabit OP JESSE JAMES8832 : It might try?